{
    "data": [
        {
            "news_url": "https://www.zacks.com/stock/news/2466329/tmdx-stock-gains-post-q1-earnings-revenue-beat-gross-margin-down?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2466329",
            "image_url": "https://cdn.snapi.dev/images/v1/8/k/f/medical30-3078672.jpg",
            "title": "TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down",
            "text": "Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.",
            "source_name": "Zacks Investment Research",
            "date": "Fri, 09 May 2025 13:05:40 -0400",
            "topics": [
                "earnings"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.fool.com/investing/2025/05/09/why-transmedics-stock-is-skyrocketing-today/",
            "image_url": "https://cdn.snapi.dev/images/v1/z/h/f/medical4-3078685.jpg",
            "title": "Why TransMedics Stock Is Skyrocketing Today",
            "text": "Shares of next-generation transplant technology platform TransMedics (TMDX 21.72%) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence.",
            "source_name": "The Motley Fool",
            "date": "Fri, 09 May 2025 12:42:32 -0400",
            "topics": [],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.investors.com/news/technology/transmedics-stock-transmedics-earnings-q1-2025/",
            "image_url": "https://cdn.snapi.dev/images/v1/g/d/8/medical3-3078444.jpg",
            "title": "Former Highflier TransMedics Catapults To Seven-Month High On Liver-Driven Beat",
            "text": "TransMedics stock rocketed Friday after the company beat Wall Street's first-quarter expectations and hiked its 2025 revenue guidance.",
            "source_name": "Investors Business Daily",
            "date": "Fri, 09 May 2025 10:06:16 -0400",
            "topics": [],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://seekingalpha.com/article/4784286-transmedics-exceptional-q1-undermines-the-short-narrative",
            "image_url": "https://cdn.snapi.dev/images/v1/g/3/j/medical19-3078051.jpg",
            "title": "TransMedics: Exceptional Q1 Undermines The Short Narrative",
            "text": "TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a boost from new heart and lung devices later in the year. While new perfusion devices are set to enter the market, TransMedics' competitive positioning appears to be extremely strong.",
            "source_name": "Seeking Alpha",
            "date": "Fri, 09 May 2025 09:48:31 -0400",
            "topics": [
                "paylimitwall"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://seekingalpha.com/article/4784113-transmedics-group-inc-tmdx-q1-2025-earnings-call-transcript",
            "image_url": "https://cdn.snapi.dev/images/v1/u/g/m/transcript7-3077215.jpg",
            "title": "TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript",
            "text": "TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Justin Wang - Morgan Stanley Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer David Rescott - Baird Mike Matson - Needham & Company Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.",
            "source_name": "Seeking Alpha",
            "date": "Thu, 08 May 2025 22:40:24 -0400",
            "topics": [
                "earnings",
                "CallScript",
                "paylimitwall"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.zacks.com/stock/news/2465727/compared-to-estimates-transmedics-tmdx-q1-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2465727",
            "image_url": "https://cdn.snapi.dev/images/v1/j/5/p/medical10-3077029.jpg",
            "title": "Compared to Estimates, TransMedics (TMDX) Q1 Earnings: A Look at Key Metrics",
            "text": "The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
            "source_name": "Zacks Investment Research",
            "date": "Thu, 08 May 2025 20:00:39 -0400",
            "topics": [
                "earnings"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.zacks.com/stock/news/2465607/transmedics-tmdx-tops-q1-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2465607",
            "image_url": "https://cdn.snapi.dev/images/v1/d/8/b/medical28-3076844.jpg",
            "title": "TransMedics (TMDX) Tops Q1 Earnings and Revenue Estimates",
            "text": "TransMedics (TMDX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.35 per share a year ago.",
            "source_name": "Zacks Investment Research",
            "date": "Thu, 08 May 2025 18:56:10 -0400",
            "topics": [
                "earnings"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.prnewswire.com/news-releases/transmedics-reports-first-quarter-2025-financial-results-302450459.html",
            "image_url": "https://cdn.snapi.dev/images/v1/r/x/b/press1-3076105.jpg",
            "title": "TransMedics Reports First Quarter 2025 Financial Results",
            "text": "ANDOVER, Mass. , May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.",
            "source_name": "PRNewsWire",
            "date": "Thu, 08 May 2025 16:05:00 -0400",
            "topics": [
                "earnings",
                "PressRelease"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1015643",
            "image_url": "https://cdn.snapi.dev/images/v1/t/o/g/press20-3075025.jpg",
            "title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Thu, 08 May 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.marketbeat.com/stock-ideas/3-mid-cap-medical-stocks-outperforming-the-market/?utm_source=snapi",
            "image_url": "https://cdn.snapi.dev/images/v1/u/2/q/biotech7-3068336.jpg",
            "title": "3 Mid-Cap Medical Stocks Outperforming the Market",
            "text": "While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.",
            "source_name": "MarketBeat",
            "date": "Tue, 06 May 2025 12:50:17 -0400",
            "topics": [],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "ADMA",
                "PEN",
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/transmedics-group-inc.-tmdx-investigation-bronstein-gewirtz-and-1015642",
            "image_url": "https://cdn.snapi.dev/images/v1/9/m/v/press9-3067732.jpg",
            "title": "TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Tue, 06 May 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.zacks.com/stock/news/2461874/insights-into-transmedics-tmdx-q1-wall-street-projections-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2461874",
            "image_url": "https://cdn.snapi.dev/images/v1/5/4/u/medical29-3064775.jpg",
            "title": "Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics",
            "text": "Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
            "source_name": "Zacks Investment Research",
            "date": "Mon, 05 May 2025 10:21:28 -0400",
            "topics": [],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-transmedics-1015641",
            "image_url": "https://cdn.snapi.dev/images/v1/w/0/d/press6-3063461.jpg",
            "title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect",
            "text": "NEW YORK, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Sun, 04 May 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-transmedics-group-1015640",
            "image_url": "https://cdn.snapi.dev/images/v1/a/i/c/press17-3058128.jpg",
            "title": "Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Thu, 01 May 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.prnewswire.com/news-releases/transmedics-to-report-first-quarter-2025-financial-results-on-may-8-2025-302437714.html",
            "image_url": "https://cdn.snapi.dev/images/v1/o/x/f/conf5-3043308.jpg",
            "title": "TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025",
            "text": "ANDOVER, Mass. , April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025.",
            "source_name": "PRNewsWire",
            "date": "Thu, 24 Apr 2025 16:05:00 -0400",
            "topics": [
                "earnings",
                "Conference"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/transmedics-group-inc-tmdx-investigation-bronstein-gewirtz-and-g-1015637",
            "image_url": "https://cdn.snapi.dev/images/v1/s/d/m/press4-3041983.jpg",
            "title": "TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Thu, 24 Apr 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.fool.com/investing/2025/04/24/1-beaten-down-stock-to-buy-right-now-and-hold-for/",
            "image_url": "https://cdn.snapi.dev/images/v1/p/k/r/medical6-3041254.jpg",
            "title": "1 Beaten-Down Stock to Buy Right Now and Hold for a Decade",
            "text": "President Donald Trump's trade war is creating significant uncertainty. Equities plunged following his decision to impose tariffs on almost every country, then soared after he announced a 90-day pause on his expanded tariff plans.",
            "source_name": "The Motley Fool",
            "date": "Thu, 24 Apr 2025 07:45:00 -0400",
            "topics": [],
            "sentiment": "Negative",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://seekingalpha.com/article/4777072-transmedics-get-some-exposure-despite-market-concerns",
            "image_url": "https://cdn.snapi.dev/images/v1/f/v/c/medical16-3037613.jpg",
            "title": "TransMedics: Get Some Exposure Despite Market Concerns",
            "text": "TransMedics recently fell over 50% due to missing analyst's expectations on revenue and EPS. Zooming out, they still grew at incredible rates and are likely to continue to do so. Key risks are a very small TAM and some financial levels deteriorating.",
            "source_name": "Seeking Alpha",
            "date": "Wed, 23 Apr 2025 04:23:29 -0400",
            "topics": [
                "paylimitwall"
            ],
            "sentiment": "Negative",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1015636",
            "image_url": "https://cdn.snapi.dev/images/v1/c/8/p/press18-3035761.jpg",
            "title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Tue, 22 Apr 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        },
        {
            "news_url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-transmedics-group-1015635",
            "image_url": "https://cdn.snapi.dev/images/v1/t/3/e/press19-3032245.jpg",
            "title": "Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation",
            "text": "NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (\"TransMedics\" or \"the Company\") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.",
            "source_name": "Accesswire",
            "date": "Sun, 20 Apr 2025 10:00:00 -0400",
            "topics": [
                "PressRelease",
                "Shareholder Alert"
            ],
            "sentiment": "Neutral",
            "type": "Article",
            "tickers": [
                "TMDX"
            ]
        }
    ]
}